Anti-Lewis Y [69/229]
Invented by Prof Lindy Durrant from University of Nottingham
Invented at University of Nottingham
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153393 |
| Applications | FACS IHC |
| Antigen/Gene or Protein Targets | Lewis Y |
| Reactivity | Human |
| Relevance | MAbs targeting both Lewis(y) and Lewis(b) may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewis(y) specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewis(b) mAb does not. This suggests that Lewis(y) but not Lewis(b) are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate. |
| Host | Mouse |
| Immunogen | Colonic Adenoma membranes |
| Subclass | IgG3 kappa |
| Myeloma Used | P3/NS1/1-Ag4.1 |
| Research Area | Cancer, Epigenetics & Nuclear Signalling |
References: 2 entries
Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949.
Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.
Europe PMC ID: 23408949
Add a reference
References: 2 entries
Noble et al. 2013. PLoS One. 8(2):e54892. PMID: 23408949.
Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.
Add a reference
